Compare NIO Inc. (NIO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Novartis AG — how do they compare? NIO Inc. trades at $4.57 (market cap $11.59B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 25.5× NIO Inc.'s market cap, and Novartis AG pays a 3.07% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | NVS | |
|---|---|---|
Market Cap | $11.59B | $295.37B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $168.62 |
52-Week Low | $4.44 | $119.31 |
Enterprise Value | $10.82B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $4.82, up 1.69% today, showing recent volatility amid mixed market signals. The company reported July 2026 deliveries growth and has beaten earnings expectations for three consecutive quarters, though it remains unprofitable with a net income margin of -9.09%. Technical indicators show neutral momentum with RSI at neutral levels, while analyst sentiment leans bullish with 54% buy ratings.
NIO presents a high-risk growth opportunity with improving revenue trends but persistent losses. The stock offers potential upside if profitability improves, but faces significant execution risks in the competitive EV market. Investors should weigh strong delivery growth against cash burn and negative equity returns before considering position entry.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
